Navigation Links
BioMS Medical announces first quarter 2008 results
Date:5/15/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"During the quarter, we completed our landmark partnership deal with Eli Lilly and Company," said Kevin Giese, President and CEO of BioMS Medical. "We now look forward to multiple clinical milestones for dirucotide (MBP8298) over the next 24 months. In the near-term, the Data Safety Monitoring Board for our MAESTRO-01 pivotal trial will review data from the first 200 patients in the trial and recommend whether the trial should continue. A positive outcome from this review, anticipated in the third quarter of 2008, is expected to trigger a milestone payment from our new partner."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating dirucotide (MBP8298) for the treatment of secondary

progressive MS (SPMS). On January 22, 2007, BioMS announced that the

trial had completed full recruitment of 611 patients at 47 trial

sites in 10 countries. Patients are administered either dirucotide

(MBP8298) or placebo every six months for a period of two years. To

date, there have been eight positive safety reviews from the

Data Safety Monitoring Board (DSMB).

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... July 30, 2014 Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended June 30, 2014 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... A study presented at the 2014 ... of CSL Behring,s C1 Inhibitor (C1-INH) concentrate in ... sensitized patients. C1-INH is a human protein and ... The study shows that post-transplant treatment with ... of complement components 3 and 4, suggesting that ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Grace Launches New REVELERIS® Prep Purification System 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3
... long-term promise, non-invasive techniques can also provide effective ... in the brain for paralyzed patients with significantly ... applications for healthy users. However, two issues hamper ... on non-invasive recording techniques, such as electroencephalography (EEG). ...
... IRVINE, Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin ... contract research, today announced financial results for the,second ... in accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ... of $0.03 per share for the,three months ended ...
... ST. LOUIS, Aug. 12 At the Board ... quarterly cash dividend of,$.13 per share. The dividend ... record on September 2, 2008., About Sigma-Aldrich: ... company. Our biochemical and organic chemical products and ...
Cached Biology Technology:ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3
(Date:7/30/2014)... black truffle uses reversible epigenetic processes to regulate its ... ,methylome, - a picture of the genome regulation taking ... access journal Genome Biology and illustrates how ... and ,jumping genes,. The authors say this may shed ... controlled. , Black truffles (Tuber melanosporum), also known as ...
(Date:7/30/2014)... protected and tended her eggs until they hatched 4.5 ... 2014 in the open-access journal PLOS ONE ... and colleagues. , Octopuses typically have a single reproductive ... take care of their fertilized eggs until they hatch. ... to 3 months, but little is known about the ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Deep-sea octopus has longest-known egg-brooding period 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... and spend enormous resources on the conservation of endangered ... One big problem is international legislation and the need ... networks. Zoo resources can be spent much more effectively, ... animal collections across the world,s zoos. Many zoos ...
... and, in most cases, they have evolved a "circadian clock". ... has been shown to have important metabolic consequences for the ... on health; for example lack of sleep is linked with ... the ability to control body weight. Scientists from the ...
... Cell Research (ISSCR) has announced the following 2014 award ... Annual Meeting in Vancouver, taking place June 18-21, 2014: ... Research UK Gurdon Institute, for the McEwen Award for ... Yale Stem Cell Center, for the ISSCR-BD Biosciences Outstanding ...
Cached Biology News:Scientists warn: Conservation work in zoos is too random 2Scientists warn: Conservation work in zoos is too random 3The internal clock and feeding rhythm set the pace of the liver 2The International Society for Stem Cell Research announces its 2014 award recipients 2The International Society for Stem Cell Research announces its 2014 award recipients 3